Method of chemotherapy for tumors of central nervous system

FIELD: medicine, oncology.

SUBSTANCE: the present innovation should be applied at adjuvant chemotherapy in case of tumors of central nervous system. Moreover, while carrying out lumbar puncture it is necessary to perform catheterization of subarachnoidal space. Moreover, one should daily sample liquor at the quantity of 10 ml to be incubated with chemopreparation in vitro for 30 min at 38 C. One should daily introduce chemopreparations upon autoliquor through catheter during the whole period of therapy course. The method enables to choose any mode and duration of endolumbar chemotherapy at its decreased toxicity.

EFFECT: higher efficiency of chemotherapy.

1 ex

 

The invention relates to medicine, namely to Oncology, and can be used in adjuvant chemotherapy of tumours of the Central nervous system (CNS).

There is a method of treatment of tumors of the Central nervous system (cm: Agiesta, Bielenski. Brain tumors of astrocytic series. Leningrad, “Medicine”, 1985, page 182): introduction of intravenous drugs according to the standard technique with individual dose calculation, and intraarterial (intracarotid) introduction of cyclophosphamide (2000 mg for 62 min), Nijana (ACNU - 2 mg per 1 kg of patient's body weight) and local use of cyclophosphamide in the tumor bed dose of 200-400 mg drawback of the methods of treatment of tumors of the Central nervous system is the high toxicity of chemotherapy are: headaches, nausea, vomiting, hyperthermia, radiation, etc.

The known method endolyumbalno the introduction of chemotherapy for tumors of the Central nervous system, selected as a prototype (see: Agiesta. Multiform glioblastoma brain, Leningrad, “Medicine”, 1976, p 178). The method includes endolyumbalno introduction of chemotherapy: maturescam 0.25 mgkg of body weight of the patient; in the course of 120-180 mg; beginning with 7-10 days after the operation, i.e. by repeated punctures (5-7 injections every other day). In some cases, there is total necrosis of the tumor.

The disadvantage of this method is the multiple punctures,burdensome for the patient in physical and moral terms. There hyperthermia, headache, nausea, vomiting.

The aim of the invention is to increase the efficiency of the method of treatment of tumors of the Central nervous system, improving conditions in anticancer therapy for patients, reducing the toxicity of chemotherapy, reducing side effects.

This goal is achieved by the fact that perform catheterization subarachnoid space, take the liquor in an amount of 10 ml, incubated with chemotherapy drugs in vitro t° 38°C for 30 min and spend prolonged administration of chemotherapy drugs on autorequire through the catheter into the subarachnoid space.

The invention “Method of chemotherapy of Opala of the Central nervous system is new, because it is not known from the level of medicine in the field of cancer chemotherapy CNS by endolyumbalno drug administration on Autostore.

The novelty of the invention lies in the fact that kateteriziruyut the subarachnoid space and put through a catheter prolonged administration of chemotherapy drugs on Autostore.

The invention is industrially applicable as it can be used in health care, in medical institutions for the treatment of patients with CNS tumours, research, cancer institutes, breast care clinics and other clinical settings.

“The way hamiter the FDI tumors of the Central nervous system” as follows: in the postoperative period the patient perform a lumbar puncture needle (Tuohy, kateteriziruyut the subarachnoid space. Take the cerebrospinal fluid of the patient in a volume of 10 ml, incubated with chemotherapy (methotrexate) in a therapeutic dose for in vitro t° 38°C for 30 min and then endolyumbalno administered to the patient. The procedure is carried out daily for 4-5 days depending on tolerability. A catheter with a pavilion for the introduction of a fix patch for the entire length on the side surface of the abdomen. After completing chemotherapy catheter removed.

A specific example of the method of treatment of tumors of the Central nervous system:

1. Askhabov A.D., 35, IB 164770. Entered INS 24.10.02, with a diagnosis of anaplastic astrocytoma frontal lobe left the state after decompressive craniotomy (26.10.02,) with Subtotal removal of the tumor. In neurological status: moderate (4 ball), right-sided hemiparesis, Opticheskie disorders, mild cerebral syndrome. Skin flap moderately preliberal. 26.10.02 was performed catheterization subarachnoid space at the level of L3-L4. Daily endolyumbalno was administered 10 mg of methotrexate, incubated with autolysosome (10 ml) at t°-38°C for 30 minutes Course of 4 days, the total dose of 40 mg In neurological status: minor strengthening of cerebral symptoms. 29.11.02, CT brain necrosis of the tumor with areas of decay and hemo is magicheskogo impregnation, marked perifocal brain edema. In neurological status: growing and cerebral pyramidal symptoms. After symptomatic and pathogenetic therapy - a positive trend.

Technical and economic efficiency “Method of treatment of tumors of the Central nervous system is that the method allows to select any mode and duration endolyumbalno chemotherapy, reduces its toxicity, does not injure the patient physically and mentally.

The way the chemotherapy of tumors of the Central nervous system, including lumbar puncture, chemotherapy, characterized in that when performing lumbar puncture perform catheterization subarachnoid space, daily take liquor in an amount of 10 ml, incubated with chemotherapy drugs in vitro, with 38°C for 30 min and daily administration of chemotherapy drugs on autorequire through the catheter during the entire course of treatment.



 

Same patents:
Antitumor agent // 2253446

FIELD: drugs, medicine.

SUBSTANCE: invention relates to application of 2-METHYL-4-chlorophenoxyacetic acid tris-(2-hydroxyethyl)ammonia salt, which represents known microorganism living function stimulator, as antitumor agent and metastasis inhibitor. Present invention makes it possible to produce drugs for treatment cancers, in particular hepatoma, melanocytoma, lymphadenoma, etc.

EFFECT: new drug for cancer treatment.

2 tbl, 2 ex

FIELD: pharmaceutical industry, in particular new bioactive chalcones.

SUBSTANCE: invention relates to new chalcones of formula I

, pharmaceutically acceptable salts or solvates thereof, wherein Ar is optionally substituted C5-C10-carbocycle group or 5- or 6-membered heterocycle group having sulfur atom in cycle, and Ar substituents are selected independently from Cl, Br, F, CN, SCH3 and OR10, wherein R10 is linear or branched C1-C6-hydrocarbon; R is OH or R10; R2 and R3 are independently phenyl, saturated linear or branched C1-C6-hydrocarbon, or R2 and R3 together with carbon atom attached thereto form 5- or 6-membered carbocycle group with the proviso, that in compounds where R is OH and both R2 and R3 are methyl, Ar is not phenyl, 4-chlorophenyl, 4-chlorophenyl, 4-methylphenyl, 2-chlorophenyl, 3,4-dimethoxyphenyl, or 4-methoxyphenyl. Also disclosed are drug component for treatment or prophylaxis of neoplasm and pharmaceutical compositions with antiproliferation effect based on compounds of formula I.

EFFECT: new chalcone derivatives with value bioactive action.

26 cl, 2 tbl, 22 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: the suggested composition includes compounds of natural ethers in cancer of mammalian soft tissues (including, the man), for example, in case of diseases of mammary gland. Both dosage and frequency of introduction depending upon a certain symptomatics could be decreased up to the level at which it is necessary to maintain improved level. At weakening the symptoms up to desired level one should stop therapy immediately. At any relapse of disease symptoms patients could need periodic therapy upon lasting basis.

EFFECT: higher efficiency of application.

2 cl, 3 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1st and the 8th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1st to the 14th d - procarbazine and prednisolone; moreover, on the 1st and the 8th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating oncological diseases. It is suggested to apply bisdioxopiperazine (previously known as cardioprotector) to either treat or prevent tissue lesions caused due to sporadic transudation of cytotoxic poison for topoisomerase II (represented by anthracyclines, etoposide, teniposide, mitoxantrone daunorubicin, doxorubicin, etc.), medicinal remedies and pharmaceutical set of the same indication. It is, also, suggested to apply the method to treat or prevent tissue lesions caused by sporadic transudation of topoisomerase II poison. BisdioxopiperazineICRF-187 has impact due to catalytic inhibiting topo II. Signs for possible transudation of topoisomerase II poison (of local toxicity) usually include the availability of acute pain, erythema, development of ulcerations in area of transudation; due to the action of ICRF-187 the quantity of wounds is reduced, or the development of side effects is not observed.

EFFECT: higher efficiency of therapy.

59 cl, 12 dwg, 13 ex, 10 tbl

FIELD: genetic engineering, in particular genes for cell cycle controlling point.

SUBSTANCE: polynucleotide encoding rad3 polypeptide ATR homologue is cloned into expression vector, having functionality in eucariotic cells. Polypeptide of rad3 polypeptide ATR homologue is obtained by cultivation of eucariotic cell culture, transformed by vector. Monoclonal antibody to rad3 polypeptide ATR homologue is obtained by hybridoma technologies. Polyclonal antibodies are obtained by inoculation of rad3 polypeptide ATR homologue in host animal. Polynucleotide presence in animal tissue sample is detected by contacting of this sample containing DNA or RNA with polynucleotide encoding rad3 polypeptide ATR homologue under hybridization conditions. Polypeptide in biological sample is detected by sample contact with monoclonal or polyclonal antibodies. Substances having anticancer activity are screened on the base of reduced activity of ATR polypeptide on substrate or reduced chelating of ATR homologue in presence of candidate substance. Present invention makes it possible to produce human or S.pombe rad3 polypeptide ATR homologue and is useful in investigation ATR role as gene for cell cycle controlling point in cell culture in vivo or in vitro.

EFFECT: new anticancer substances.

24 cl, 1 dwg

FIELD: organic chemistry, pharmacology.

SUBSTANCE: invention relates to new flavone, xanthone and coumarone derivatives of formula I

[R and R1 each are independently lower C1-C6-alkyl or together with nitrogen atom attached thereto form 4-8-membered heterocycle, optionally containing one or more heteroatoms, selected from group comprising N or O, wherein said heterocycle is optionally substituted with benzyl; Z has formula (A) , wherein R3 and R4 each are independently hydrogen, optionally substituted aromatic group containing in cyclic structure from 5 to 10 carbon atoms, wherein substituents are the same or different and represent lower C1-C4-alkyl, OR10 (OR10 is hydrogen, saturated or unsaturated lower C1-C6-alkyl or formula ) or linear or branched C1-C6-hydrocarbon; or R2 and R3 together with carbon atom attached thereto form 5-6-membered carbocycle; and R4 represents hydrogen or attaching site of group –OCH2-C≡CCH2NRR1; or formula (B) , wherein R5 is hydrogen, linear or branched lower C1-C6-hydrocarbon, with the proviso, that when Z represents R and R1 both are not methyl or R and R1 together with nitrogen atom attached thereto cannot form groups , or ]. Also disclosed are drug component with proliferative activity for prophylaxis or treatment of neoplasm and pharmaceutical composition with proliferative activity based on the same. Derivatives of present invention have antyproliferative properties and are useful as modulators of drug resistance in cancer chemotherapy; as well as in pharmaceuticals for prophylaxis or treatment of neoplasm, climacteric disorders or osteoporosis.

EFFECT: new compounds with value bioactive effect.

31 cl, 2 tbl, 32 ex

FIELD: medicine.

SUBSTANCE: after keeping during pharmaceutically acceptable period oxaliplatinum is placed in transparent, colorless and residue-free solution at concentration of, at least, 7 mg/ml, and a solvent contains sufficient quantity of, at least, one hydroxylated derivative chosen among of 1.2-propandiol, glycerol, maltite, saccharose and inositol. The innovation describes the way to obtain such a preparation. The preparation is stable during pharmaceutically acceptable period of time, that is it remains transparent, colorless and free of any residue within the range of 2-30 C that could be available during its transportation, storage and/or any handling.

EFFECT: higher efficiency of application.

14 cl, 6 ex, 4 tbl

FIELD: biochemistry.

SUBSTANCE: invention relates to method for production of synthetic chlorophyll (Chl) or bacteriochlorophyll (Bchl) derivatives of general formula I , wherein X is O;. Claimed method includes interaction under anaerobic conditions of Chl, Bchl derivatives containing COOCH3-group in C-132-position and COOR3-group in C-172-position in presence of tetraethyl orthotitanate. Further compounds of formula I wherein R1 and R2 are different radicals are obtained in aproton solvent such as peroxide-free tetrahydrofurane and dimethyl formamide, and compounds of formula I wherein R1 and R2 are the same ones are produced by using R1OH as a solvent. Derivatives of present invention are useful as stabilizers, linkage/spacer for binding another acceptable molecules to Chl/Bchl macrocycle.

EFFECT: simplified method for production of various chlorophyll or bacteriochlorophyll derivatives.

13 cl, 3 ex, 2 tbl, 8 dwg

FIELD: organic chemistry and medicine.

SUBSTANCE: invention relates to new imidazole derivatives of general formula I useful as adenosine A3-receptor modulators, as well as to method for cancer treatment and detection of tumor cells using claimed derivatives.

EFFECT: compounds for treatment and diagnosis of improved activity.

13 cl, 4 dwg, 19 ex

FIELD: medicine.

SUBSTANCE: method involves determining required foramen level. Needle is introduced at lumbar, sacral and thoracic segment level in paravertebral way with posterolateral access method and with anterolateral access at the cervical segment level. Tuochi 16-20 needle is applied. The needle is introduced 7-12 cm far from vertebral column median in the direction of intervertebral foramen at an angle of 50-80° to table surface in prone patient position at lumbar, sacral and thoracic segment level. The needle is brought in sliding in lateral direction after it has rested against joint facet. The needle is introduced towards the intervertebral foramen in dorsal patient position. Then, the needle slides from the transverse process in ventral direction. Short-term pain increase being the case, drugs are introduced.

EFFECT: enhanced effectiveness of treatment.

The invention relates to medicine, in particular to cancer, and can be used in the treatment of locally common forms of lung cancer, including inoperable

The invention relates to medicine, more specifically to Oncology, and can find application in the treatment of colon cancer with liver metastases

The invention relates to medicine, in particular to cancer, and can be used for the treatment of patients with cancer of the oral cavity and the oral part of the throat

The invention relates to medicine, namely to neurosurgery

The invention relates to medicine, and is intended for monitoring violations of hepatic blood flow during surgical and postoperative periods hepatectomy

The invention relates to medicine, more specifically to Oncology, and can be used in the treatment of patients with malignant prostate tumors with a significant prevalence of process

The invention relates to medicine, namely to surgery

The invention relates to medicine, namely to surgery, and may be applicable for indirect access into the cavity of the duodenum
The invention relates to medicine, surgery

FIELD: medicine.

SUBSTANCE: method involves determining required foramen level. Needle is introduced at lumbar, sacral and thoracic segment level in paravertebral way with posterolateral access method and with anterolateral access at the cervical segment level. Tuochi 16-20 needle is applied. The needle is introduced 7-12 cm far from vertebral column median in the direction of intervertebral foramen at an angle of 50-80° to table surface in prone patient position at lumbar, sacral and thoracic segment level. The needle is brought in sliding in lateral direction after it has rested against joint facet. The needle is introduced towards the intervertebral foramen in dorsal patient position. Then, the needle slides from the transverse process in ventral direction. Short-term pain increase being the case, drugs are introduced.

EFFECT: enhanced effectiveness of treatment.

Up!